- Free from Publisher LS Cozma, SD Luzio, GJ Dunseath, PM … - Diabetes care, 2005 - Am Diabetes Assoc RESULTS—The insulinogenic index (ΔI30/ΔG30) and insulin area under the curve
(AUC) from 0 to 30 min (AUC 0–30 ) were higher with the 4-mg drug dose
compared with the two lower doses and with 2 mg compared with 0.5 mg. On ... Cited by 7 - Related articles - All 5 versions
[CITATION] Effect of a prandial glucose regulator (NovoNorm®) at two doses (0.5 mg and 2.0 mg) on …
LS Cozma, SD Luzio, GJ Dunseath, PM … - Diabetes Care, 2005 - Am Diabetes Assoc Page 1. -Cell Response During a Meal Test A comparative study of incremental
doses of repaglinide in type 2 diabetic patients L AWRENCE ... Related articles
EJ Abbink, PS van der Wal, CGJF Sweep, P … - Diabetes/Metabolism Reviews - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 4 - Related articles - BL Direct - All 5 versions
- ►endojournals.org W Aldhahi, J Armstrong, C Bouche, RD Carr, … - Journal of Clinical Endocrinology & Metabolism, 2004 - Endocrine Soc Oral hypoglycemic agents bind to the ATP-sensitive potassium channel and lower
glucose levels effectively in individuals with diabetes. Although the principle
mechanism of action can also promote hypoglycemia, clinically profound ... Cited by 4 - Related articles - BL Direct - All 4 versions
C Rosak, U Hofmann, O Paulwitz - Diabetes, nutrition & metabolism(Testo stampato), 2004 - cat.inist.fr This study was designed to compare the effects of repaglinide plus acarbose
combination treatment to repaglinide alone on postprandial glucose, serum
insulin, C-peptide and proinsulin concentrations. A total of 40 patients ... Cited by 5 - Related articles - BL Direct - All 2 versions
EH Johanson, PA Jansson, B Gustafson, M … - Diabetes/Metabolism Reviews - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 6 - Related articles - All 4 versions
S Miwa, H Watada, C Ohmura, Y Tanaka, R … - Endocrine journal, 2004 - ncbi.nlm.nih.gov An open-label prospective cross-over trial was performed to compare the efficacy
and safety of once daily low-dose gliclazide (20 mg/day) with that of
nateglinide at the usual dosage (270 mg/day, 90 mg tid) in Japanese type 2 ... Cited by 6 - Related articles - BL Direct - All 3 versions
KC Maki, JM McKenney, MV Farmer, MS … - Nutrition Journal, 2009 - biomedcentral.com Address: 1Provident Clinical Research, Bloomington, IN, USA, 2National Clinical
Research, Richmond, VA, USA and 3Meridien Research, St Petersburg, FL, USA
Email: Kevin C Maki* - kmaki@providentcrc.com; James M McKenney - JMcKenney@ ... Related articles - View as HTML - All 9 versions
